Davide Ruggero

City College of San Francisco — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

59h-index25.0kcitations230works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(61), RNA and protein synthesis mechanisms(57), PI3K/AKT/mTOR signaling in cancer(40), RNA Research and Splicing(31), Prostate Cancer Treatment and Research(26)

Publications226 total

Supplementary Data from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
2025Open Access
Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
2025Open Access
Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
2025Open Access
Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
2025Open Access
CNSC-40. DECIPHERING CELLULAR TRANSLATION CONTROL IN NEURON-GBM INTERACTIONS
Neuro-Oncology·2025Open Access
NOVA: a novel R-package enabling multi-parameter analysis and visualization of neural activity in MEA recordings
2025Open Access
Programmable translational inhibition by a molecular glue-oligonucleotide conjugate
2025Open Access
Small-molecule RNA therapeutics to target prostate cancer
Cancer Cell·2025· 13 cited
Breaking up translation condensates in cancer
Nature Cell Biology·2025· 1 cited
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Morgan Truitt(7), Andrew C. Hsieh(6), Kevan M. Shokat(6), Pier Paolo Pandolfi(6), Craig R. Stumpf(5), Nahum Sonenberg(4), John T. Cunningham(4), Feven Tameire(4), Constantinos Koumenis(4), Maria Barna(4), Crystal S. Conn(4), Cristian Bellodi(4), Morris E. Feldman(3), Ornella Zollo(3), Serge Y. Fuchs(3), J. Alan Diehl(3), Eduardo Magalhães Rego(3), Noam E. Kopmar(3), Yichen Xu(3), Craig M. Forester(3)